

## *Curriculum Vitae*

**Jürgen Behr** Professor, Dr. med.  
d.o.b. September 06th, 1960, in Bamberg, Germany

### **University Education**

1996 Habilitation Internal Medicine, LMU  
1987 Doctorate Medicine, LMU  
1979 - 1985 Studies of medicine at the Ludwig-Maximilians University of Munich (LMU)

### **Scientific Career**

Since 2013 Professor of Medicine and Chair Pneumology, Director of the Department of Medicine V, LMU  
Since 2013 Co-Chair Comprehensive Pneumology Center, Ludwig-Maximilians University, University Hospital Munich, Helmholtz Zentrum Munich, and Asklepios  
Since 2013 P.I. of the German Center for Lung Research (DZL)  
Since 2020 Consultant Professor at the Asklepios Fachkliniken München-Gauting  
2013–2020 Medical Director of Asklepios Fachkliniken München-Gauting  
2010-2012 Professor of Medicine and Chair Pneumology, Department of Internal Medicine III – Pneumology, Ruhr-University-Bochum, Germany  
2002-2010 Associate Professor of Internal Medicine, Respiratory Diseases  
2001-2010 Head of Div. of Respiratory Diseases, Department of Internal Med. I, LMU  
1997-2001 Attending Physician of the Intensive Care Unit (1997-98) and of the Div. of Pulmonary Diseases (1998-) at the Department of Internal Medicine I, LMU  
1986–1996 Internship and Residency, Department of Internal Medicine I, LMU

### **Awards and Honors**

2019 President of the National Congress, German Respiratory Society (DGP)  
2016-2018 Chairman Scientific Association for the Treatment of Lung Diseases (WATL)  
2016 Congress President “Rare Lung Diseases” (WATL), Berlin, Germany  
2014 Co-Chair Annual Congress of the European Respiratory Society, Munich, Germany  
Since 2013 Chair Stiftung Atemweg  
2009-2013 ERS Delegate of the ATS/ERS Interstitial Lung Disease Classification Committee  
2008-2012 ERS Delegate of the ATS/ERS Lung Transplantation Guideline Committee  
Since 2002 Chair Guideline Committee, German Respiratory Society (DGP)  
2006 - 2018 ERS Delegate of the ATS/ERS/JRS/ALAT IPF-Guideline Committee  
1979 - 1985 Stipendium – Bayerische Begabtenförderung

### **Citation Record**

*Total citations: 90,910; h-index:123 h-index since 2017: 80 (Google Scholar July 22<sup>th</sup>, 2022)*

## Top-10 selected Publications

Raghu G, Mouded M, Chambers DC, ..., Violette SM, Gallagher D, **Behr J**. A Phase IIb Randomized Study of an Anti- $\alpha\text{v}\beta 6$  Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2022 Jun 30. doi: 10.1164/rccm.202112-2824OC. Epub ahead of print. PMID: 35771569.

**Behr J**, Prasse A, Kreuter M, ..., Welte T, Neuser P, Günther A; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30. PMID: 33798455.

**Behr J**, Nathan SD, Wuyts WA, ..., Perjesi A, Harari S, Wells AU. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2021 Jan;9(1):85-95. doi: 10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18.

Strunz M, Simon LM, Ansari M, Kathiriya JJ, Angelidis I, Mayr CH, Tsidiridis G, Lange M, Mattner LF, Yee M, Ogar P, Sengupta A, Kukhtevich I, Schneider R, Zhao Z, Voss C, Stoeger T, Neumann JHL, Hilgendorff A, **Behr J**, O'Reilly M, Lehmann M, Burgstaller G, Königshoff M, Chapman HA, Theis FJ, Schiller HB. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. *Nat Commun*. 2020 Jul 16;11(1):3559. doi: 10.1038/s41467-020-17358-3. PMID: 32678092; PMCID: PMC7366678.

**Behr J**, Prasse A, Wirtz H, ..., Oqueka T, Frankenberger M, Kreuter M. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. *Eur Respir J*. 2020 Aug 13;56(2):1902279. doi: 10.1183/13993003.02279-2019. PMID: 32381492.

Nathan SD, **Behr J**, Collard HR, Cottin V, Hoepfer MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. *Lancet Respir Med*. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12. PMID: 31416769.

Kolb M, Raghu G, Wells AU, **Behr J**, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. PMID: 30220235.

**Behr J**, Bendstrup E, Crestani B, ..., Lin CY, Beck J, Albera C. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5. PMID: 27161257.

Demedts M, **Behr J**, Buhl R, ..., Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med*. 2005 Nov 24;353(21):2229-42. doi: 10.1056/NEJMoa042976. PMID: 16306520.

Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoepfer MM, **Behr J**, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*. 2002 Aug 1;347(5):322-9. doi: 10.1056/NEJMoa020204. PMID: 12151469.